Picture
 

FOUR Fighters Flunk Drug Tests at Bellator 127

Written by Tom Ngo
October 31st, 2014
Share on Facebook0Google+0Tweet about this on Twitter

Bellator Rob Emerson UFC

It’s not often that you hear about Bellator MMA guys flunking their drug tests, that’s mainly left up to the UFC’s athletes these days, but when it happens it apparently comes in bunches.

Four of the 22 fighters who competed at Bellator 127 inside Pechanga Resort and Casino in Temecula, California on October 3 failed their drug exams. That’s right, FOUR on one card!

Bellator confirmed Friday that Rob Emerson (pictured), Keith Berry, Nick Moghaddam and Fernando Gonzalez all tested positive for banned substances.

The prescription drug Modafinil, which is recreationally used by those looking for a pick-me-up, was found in Emerson’s system.

Emerson dropped a unanimous decision to Rafael Silva that evening.

Berry tested positive for elevated testosterone levels, as well as marijuana. His split decision win over Joe Pacheco will be overturned to a no contest.

Moghaddam was also popped for testosterone and weed. “The Zen Master” lost his bout against Ray Sloan via unanimous decision.

Gonzalez didn’t need the help of testosterone to knockout Karo Parisyan, just cannabinoids.

“I want to make very clear that under new management, Bellator will simply not stand for performance enhancing drugs inside our cage,” Bellator president Scott Coker said. “We fully support the California State Athletic Commission in their process, and standby any disciplinary action handed out by Commissioner Andy Foster and the CSAC. Fans, media and our athletes need to have a clear understanding that drug use will simply not be tolerated by Bellator.”

The California Ste=ate Athletic Commission is still ironing out penalties for everyone except Berry.

Former Bellator welterweight champion Ben Askren claimed in May 2013 that the promotion barely ever tests its fighters. Maybe it should start doing so on a more consistent basis…

Don’t forget to follow @5thRound on Twitter, Facebook and Google+!



COMMENTS